Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | GALR2 | O43603 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | VCP | P55072 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221924 | 0.98 | HTT (0.66) | HTTTDP1PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL31493924 | 0.98 | HTT (0.66) | HTTTDP1PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL8627823 | 0.96 | HTT (0.64) | HTTTDP1PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL31296069 | 0.96 | HTT (0.64) | HTTTDP1PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL1531372 | 0.96 | HTT (0.64) | HTTTDP1PKMALDH1A1SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL28302337 | 0.96 | HTT (0.64) | HTTTDP1PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL22534526 | 0.96 | HTT (0.64) | HTTTDP1PKMALDH1A1SMN1; SMN2 | |
| Phosphoric Acid SCHEMBL27916059 | 0.92 | HTT (0.58) | HTTTDP1PKMALDH1A1SMN1; SMN2 | |
| Phosphoric Acid SCHEMBL28200300 | 0.89 | HTT (0.55) | HTTTDP1PKMALDH1A1SMN1; SMN2 | |
| Monoethanolamine SCHEMBL28300774 | 0.88 | HTT (0.58) | HTTTDP1PKMALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346872-B1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-11-25 | — | — | EP | disclosed |
| US-8754211-B2 | Azolotriazinone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140031337-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-30 | — | — | US | disclosed |
| US-8618115-B2 | Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-31 | — | — | US | disclosed |
| US-8580959-B2 | Azolotriazinone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| EP-1948665-B1 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-27 | — | — | EP | disclosed |
| US-8344160-B2 | Pyrrolone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2346860-B1 | PYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20110218185-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | SYNGENE INTERNATIONAL LIMITED (IN) | 2011-09-08 | — | — | US | disclosed |
| US-20110195986-A1 | PYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| WO-2007050723-A1 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20060173034-A1 | Novel 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | US | disclosed |
| US-7037925-B2 | 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2006-05-02 | — | — | US | disclosed |
| US-20040248923-A1 | Novel 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | US | disclosed |
| EP-1387830-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | AstraZeneca AB (SE) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002092571-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | disclosed |
| EP-0603964-B1 | Azopyrazolone masking couplers | EASTMAN KODAK CO (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5492799-A | Azopyrazolone masking couplers | EASTMAN KODAK COMPANY (US) | 1996-02-20 | — | — | US | disclosed |
| EP-0603964-A2 | Azopyrazolone masking couplers | EASTMAN KODAK COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248923-A1 | Novel 4-anilinoquinoline-3-carboxamides | JAK3, JAK2, JAK1 | HTT 4311/4885TDP1 4594/4885PKM 1960/4885 |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | MCHR1, MCHR2, MC1R | HTT 704/4885TDP1 2046/4885PKM 766/4885 |
| US-20110195986-A1 | PYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | HTT 705/4885TDP1 2301/4885PKM 636/4885 |
| US-20060173034-A1 | Novel 4-anilinoquinoline-3-carboxamides | JAK3, JAK2, JAK1 | HTT 3432/4885TDP1 3868/4885PKM 2508/4885 |
| US-20140031337-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | HTT 965/4885TDP1 3281/4885PKM 1661/4885 |
| US-20110218185-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | HTT 965/4885TDP1 3281/4885PKM 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.